Lederman Seth
LEDERMAN SETH, CEO, reported an open-market or private purchase at Tonix Pharmaceuticals Holding Corp. involving 2000.000000 shares for an estimated $27580.00. Reported holdings after the transaction were 11005.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
- Trade date
- Aug 27, 2026
- Filing date
- Aug 31, 2026
How reported position traded is calculated
Shares purchased ÷ (holdings after − shares purchased). Estimated position before: 9,005 shares.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
TNXP price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- Buy Code P
- Identifier
- 0001493152-26-040736 Common Stock, $0.001 par value
- Transaction date
- Aug 27, 2026 Filed Aug 31, 2026, 12:00 PM · 4d delay
- Shares
- 2,000 sh $13.79 per share
- Estimated value
- $27.5k Computed from shares × price
- Holdings after
- 11,005 sh Indirect · By IRA Account
Filing signal explanations
Badges describe filing facts only — not predictions.
+24 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a modest positive filing-only score. Treat it as a useful flag for review, not as a buy signal.
How this score is calculated
- open_market_purchase+12 points
transaction_code = P
Code P is a discretionary open-market purchase. - ceo_buy+12 points
is_officer + officer_title/role mentions CEO
CEO open-market purchase.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
Chief Executive Officer
- F1
Reporting person may be deemed a control person of this entity.
0 other transactions
0 recent txs